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Summary Analyses of prognostic factors have allowed the design of staging systems in different
haematological disorders. In a series of 220 patients with multiple myeloma, univariate analysis showed that
nine parameters had a significant adverse effect on survival; poor performance status (Karnowsky scaling
system < 70%), infections before diagnosis, renal impairment (assessed either by creatinine
clearance > 2 mgdl 1 or urea > 40 mgdl 1), serum calcium (> O0 mgdl 1), severe anaemia (< 8.5 gdl 1), the
presence of Bence-Jones proteinuria, failure to achieve complete remission, more than 40% plasma cells in
bone marrow and a low paraprotein index (monoclonal component/% plasma cells: P < 0.09). In addition,
this index correlated significantly with all the other prognostic factors except performance status. The best
combination of disease characteristics selected by means of the Cox regression proportional hazards method
were performance status and creatinine levels. Additionally, by factor analysis of principal components we
obtained a regression equation that included creatinine levels, haemoglobin, performance status and
paraprotein index. Using this it was possible to separate the series of patients into three risk categories: A (65
patients), B (69 patients) and C (65 patients) with a median survival of 41, 24 and 12 months, respectively.
The model provided similar results to those of the British Medical Research Council, whereas the staging
systems proposed by Durie and Salmon, Merlin et al. and Carbone et al. had a lower discriminant value in
our series.
Patients with multiple myeloma (MM) display a very hetero-
geneous clinical and biological course, their survival ranging
from a few months to more than 5 years (Durie & Salmon,
1982; Hansen & Galton, 1985; Kyle, 1984). Analysis of
prognostic factors has permitted the design of staging
systems that will facilitate the prognostic categorisation of
patients and the evaluation of different treatment protocols.
However, even within a single clinical stage there continue to
be patients with considerable clinical variability, which
necessitates the search for new parameters that will allow a
better individual control of each patient. Moreover, some of
the classification models proposed (Durie & Salmon, 1975;
Merlini et al., 1980) have shown poor discriminatory power
when assayed in other series of patients (Bettini et al., 1983;
Blad& & Rozman, 1984; Durie et al., 1980; Gavagnaro et al.,
1980; Hansen et al., 1973; Hernandez & San Miguel, 1984;
Pennec et al., 1983; Vercelli et al., 1981).
Most of these studies have been performed on the basis of
univariate analysis (Adachi et al., 1982; Bartl et al., 1982;
Bergsagel et al., 1979; Brian et al., 1980; Buckman et al.,
1982; Carbone et al., 1967; Costanzi et al., 1985; Harley et
al., 1979; Pesce et al., 1983; Vercelli et al., 1980, 1981), there
being few works that use multivariate methods (Blade &
Rozman, 1984; Cohen et al., 1979; Durie & Salmon, 1975;
Durie et al., 1980; Hernandez & San Miguel, 1984; Kyle,
1983, 1984; Matzner et al., 1978; Merlini et al., 1980) and to
the best of our knowledge none has employed factor analysis
by the principal components method.
The aim of the present study was to identify significant
prognostic factors in a series of 220 MM patients.
Additionally, an attempt was made to develop a staging
system from the results of such analysis and compare this
with other well-established systems (Carbone et al., 1967;
Durie & Salmon, 1975; Medical Research Council's Working
Party on Leukaemia in Adults, 1980; Merlini et al., 1980).
Materials and methods
Patients, diagnostic criteria, treatment and survival
A total of 220 patients diagnosed as MM according to the
criteria of the Chronic Leukemia-Myeloma Task Force
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(Committee of Chronic Leukemia-Myeloma Task Force,
1973) were evaluated. Fifty-three per cent of the patients
were treated with melphalan and predisone and the
remaining 47% with different protocols, including VCMP,
VCAP amd M2. No differences were seen in the survival of
the patients according to the treatment employed. The
median survival (calculated from the time of diagnosis up to
the time of death or that of closing the study) for the whole
series was 24.3 months. Early deaths were also included and
32% of the patients are still alive.
Parameters evaluated. In each patient the following clinical
and laboratory characteristics documented at diagnosis as
well as subsequent details of response to therapy were
evaluated for their prognostic significance: (1) clinical
features such as age, sex, performance status (Karnofsky
scale), previous episodes of infection or haemorrhage, spleen
and liver enlargement and amyloidosis; (2) peripheral blood
parameters, including haemoglobin concentration (Hb),
white blood cell (WBC) and differential counts, platelet
counts, erythrocyte sedimentation rate (ESR); (3) serum
biochemical data such as uric acid, calcium corrected for
albumin, creatinine, blood urea nitrogen (BUN), phosphate,
serum alkaline phosphatase, glutamic oxalacetic
transaminase (SGOT) and glutamic pyruvic transaminase
(SGPT); (4) electrophoretic data, including total serum
protein and albumin, serum and/or urinary monoclonal
component level, type of heavy and light chain; (5)
percentage of bone marrow plasma cells; (6) bone lesions
scaled according to Durie and Salmon's criteria; and (7) a
new parameter, the paraprotein index (PI) the objective of
which is to evaluate the amount of monoclonal component
(MC) secreted in serum or urine per 1% of plasma cells; this
was calculated for each patient by the following expression:
PI=MC (gdl-1)/% of BM plasma cells.
Classifications
The patients' survival was analysed according to'the criteria
of the following staging systems: Durie & Salmon (1975),
Merlini et al. (1980), Carbone et al. (1967) and the British
Medical Research Council (1980). A patient was considered
as wrongly classified when a significant discordance was
observed between the real survival and that expected
according to the clinical stage assigned.
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Statistical analysis
Survival curves were plotted according to the method of
Kaplan & Meier (1958), and statistically compared using the
Mantel-Cox and Breslow tests. Thirty disease characteristics
were considered individually for their relationship with
survival (univariate analysis, BMDP IL) (Dixon, 1985; Cox
& Dakes, 1985). The cut-off of each parameter was selected
by starting at its median value and then cutting at different
levels above and below, until significance was eventually
obtained.
Subsequently, a multivariate analysis was performed to
examine the simultaneous effect of the different variables on
survival by the stepwise proportional hazards regression
model for censored survival data (BMDP 2L) (Cox, 1972).
Variables considered for possible inclusion in the Cox
regression analyses were those for which there was some
indication of a significant association with survival in
univariate analysis (P < 0.10) or for which prior studies had
suggested a possible association. The model was tested twice
by expressing the values in a continuous way (continuous
model) and by grouping into categories (binary model). The
most discriminant cut-off level was employed to define
categories of variables in the binary model. Additionally, by
factor analysis of principal components (BMDP4M
program) we obtained a regression equation with which we
could separate the patients into three risk groups according
to their relative risk score.
Results
The univariate analysis showed that nine parameters had a
significant adverse effect on survival (Table I): poor
performance status (Karnofsky scaling system <70%),
infections before diagnosis, renal impairment (assessed either
by creatinine clearance >2mgdl-1 or urea >40mgdl-1),
serum calcium (>10mgdl-1), severe anaemia (<8.5gdl-1),
presence of Bence-Jones proteinuria, failure to achieve
complete remission, more than 40% plasma cells in bone
marrow and a low paraprotein index (<0.09). The median
value for this latter parameter in our series was 0.1 and in
addition, the paraprotein index correlated significantly with
all the other prognostic factors except performance status
(Table II).
The best combination of patients and disease
characteristics selected by means of the Cox regression
proportional hazards method both in the binary and
continuous models were the performance status and the
creatinine level (Table III). Since performance status could
be considered as a subjective measurement, a new regression
analysis excluding this variable was performed, the
characteristics selected being creatinine level (P < 0.0004) and
haemoglobin (P < 0.02).
The principal component analysis showed that the four
variables that had the highest correlation with the first
component were creatinine, haemoglobin, performance status
and paraprotein index. A new principal component analysis
based on these four parameters yielded the regression
equation shown in Table IV. Upon applying this equation
for each patient, the score values ranged between -2.4 and
+2.4, which in turn pointed to a significant correlation with
the survival of the individual patients (Pearson test
P < 0.001). Using two cut-off points at -0.05 and +0.05 the
series of patients was divided into three risk categories: A
(65 patients), B (69 patients) and C (65 patients) with
median survivals of 41.3, 24 and 12.7 months, respectively
(Figure 1). These categories were not only significantly
different according to survival but also in the distribution of
othqlr prognostic factors whose incidence increased
significantly from stage A to B and from B to C (Table V).
Upon comparing this staging system with another four
reported previously that divide MM patients into three or
more categories (Durie & Salmon, 1975; Merlini et al., 1980;
Table I Prognostic factors obtained in the univariant analysis
No. of Survival in
Factors cases months P
Anaemia
K8.5gddl' 47 17.5 0.05
>8.5gdl-1 163 26.9
Urea
,<40mgdl-' 67 32.9 0.002
>40mgdl-' 134 20.5
Serum calcium
,<10mgdlP' 131 25.9 0.02
>lOmgdlP' 79 21.3
% Plasma cell
<400% 115 27.0 0.01
>40% 87 18.6
Renal insufficiency
A (Cr. <2mgdlP') 152 26.9 0.0001
B (Cr. >2mgdP1) 63 15.9
Infections
Yes 63 19.2 0.05
No 141 26.6
Performance status
<70 144 20.6 0.001
>70 71 44.8
Bence-Jones proteinuria
Yes 87 22.9 0.05
No 79 29.8
Paraprotein index
<0.09 90 19.9 0.003
>0.09 109 25.5
Table II Distribution of prognostic factors according to the para-
protein index (PI)
Patients with Patients with
Factors PI<0.09 (%) PI>0.09 (%) P
Anaemia
<8.5 34.3 22.3 0.04
>8.5 65.7 77.7
% Plasma cells
<40% 26 80.2 0.00005
>40% 74 19.8
Urea
<40mgdl-1 21 46.4 0.0001
>40mgdl-1 79 19.8
Renal insufficiency
No 60.6 85.1 0.00005
Yes 39.4 14.9
Clinical staginga
I 8.7 15.8 0.05
II 32.7 36.7
III 58.7 47.5
Skeletal lesions
0 or 1 28 42 0.05
2 or 3 72 58
Type of myeloma
IgG 51.5 58.3 0.007
IgA 28.9 35.8
BJ 19.6 5.8
Serum calcium
< 10mgdl-' 54.9 70.3 0.01
>lOmgdl-' 45.1 29.7
Infections
Yes 36.5 24.8 0.05
No 63.5 75.2
Bence-Jones proteinuria
Yes 46.0 56.0 0.14
No 54.0 44.0
Performance status
<70 71.2 64.5 0.2
>70 28.8 35.5
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Table III Cox model relating pretreatment characteristics to survival duration (order of variables
entering the regression and level of significance and relative risk)
Relative risk
P P
Factors Code Coefficient partial total Favourable Unfavourable Rat
Performance status
K70 1 -0.8452 0.00005 0.0001 0.56 1.31 2.33
>70 2
Renal insufficiency
Yes 1 0.7204 0.0004 0.00005 0.82 1.70 2.07
No 2
% Plasma cells
<40% 1 0.2413 0.20 0.00005 0.90 1.15 1.27
>40% 2
Ln (L{(t)/l(lo)}=-0.8452 x (Karnofsky- 1.32) + 0.7304 x (IR- 1.27).
Table IV Equation obtained by princi-
pal component analysis
Factors Cl
(Hb) Anaemia 0.44347
(I) Renal insufficiency -0.38982
(PS) Performance status 0.35096
(PI) Paraprotein index 0.29178
Score=Hb x 0.44347 - RI x 0.38982+
PS x 0.35096 + PI x 0.29178.
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Table V Distribution of patients with unfavorable prognostic
factors in the three group categories proposed
Clinical stage (%)
Factors
Anaemia
K8.5
>8.5
% Plasma cells
<40%
>40%
Urea
<40mgdl-1
>40mgdl-'
Renal insufficiency
No
Yes
Serum calcium
< 10mgdl-
>lOmgddl
Infections
Yes
No
Bence-Jones proteinuria
Yes
No
Performance status
<70
>70
Paraprotein index
<0.09
>0.09
A B C P
0.0 20.7 66.2
100.0 79.3 33.8
87.7 42.7 36.8
12.3 57.3 63.2
66.7 29.1 7.7
33.3 70.9 92.3
100.0 92.7 23.5
0.0 7.3 76.5
64.3 72.0 51.5
35.7 28.0 48.5
30.1 24.4 38.2
61.8 75.6 69.8
50.0 52.6 51.5
50.0 47.4 48.5
38.4 78.0 85.3
61.6 22.0 14.7
26.0 46.3 66.2
74.0 53.7 33.8
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Figure 1 Staging system of Group Castellano Leones, classifica-
tion 1. A, 41 months; B, --- 24 months; C, 12
months. A versus B versus C, P<0.01.
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Figure 2 Staging system of Durie & Salmon (1975). Stage I,
56 months; stage II, --- 26 months; stage III, 21
months. I versus II and III, P<0.03; II versus III, n.s.
Carbone et al., 1967; Medical Research Council, 1980), we
observed that only the latter permits separation of
significantly different patient populations according to
survival (Figures 2-5). The survival curves obtained with the
MRC staging system were very similar to those obtained
with our regression model, although in the model we
propose distribution of the patients into the three stages was
more uniform and the proportion of wrongly classified
patients was lower (35% in the MRC model versus 24% in
our model). Moreover, a simplified risk group assignment
(Table VI) provided very similar results (Figure 6).
Discussion
Multiple myeloma is one of the diseases in which prognostic
factors have been most extensively investigated (Adachi et
al., 1982; Blade & Rozman, 1984; Brian et al., 1980;
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Figure 3 Staging system of Merlini et al. (1980). Stage I,
30 months; stage II, --- 23 months; stage III 19 months. I
versus III, P < 0.05; I versus II and II versus III, n.s.
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Figure 4 Staging system of Carbone et al. (1967). 0 risk factor,
30 months; risk factor, --- 28 months; 2 risk factor,
15 months; 3 risk factor, 12 months. 0 and I versus 2
and 3, P<0.000l.
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Figure 5 Staging system of the MRC (1980). Stage A, 46
months; stage B, --- 23 months; stage C, -- 13 months. A
versus B versus C, P<0.0l.
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Figure 6 Staging system of Group Castellano Leones, classifica-
tion 2. Stage A, 46 months; stage B, --- 23 months: stage
C, - 13 months. A versus B versus C, P<0.0l.
Table VI Criteria for a simplified risk group assignment
Unfavourable characteristics Risk group
Anaemia < 8.5 gdl- l A No unfavourable characteristics
Renal insufficiency (cr. >2mgdl-1) B 1 or 2 unfavourable characteristics
Performance status < 70% C 3 or 4 unfavourable characteristics
Paraprotein index < 0.09
Carbone et al., 1967; Costanzi et al., 1985; Durie & Salmon,
1975; Durie et al., 1980; Hansen & Galton, 1985; Hernandez
& San Miguel, 1984; Matzner et al., 1978); this has led to
the description of numerous staging systems (Alexanian et
al., 1975; Costa et al., 1973; Durie & Salmon, 1975; Medical
Research Council's Working Party on Leukaemia in Adults,
1980; Merlini et al., 1980; Southeastern Cancer Study
Group, 1975). However, few critical papers have been
devoted to such classifications (Bettini et al., 1983;
Cavagnaro et al., 1980; Gassmann et al., 1985; Pennec et al.,
1983; Vercelli et al., 1981) and in fact the model of Durie &
Salmon (1975) continues to be the most popular one despite
several studies having thrown doubt on its real prognostic
value (Blade & Rozman, 1984; Durie et al., 1980; Gavagnaro
et al., 1980; Hern'andez & San Miguel, 1984; Merlini et al.,
1980; Yercelli et al., 1981). In the present work, apart from
analysing four of the most popular staging systems, a new
model is proposed that was obtained by statistical analysis of
principal components; this model also includes a new
parameter that relates the monoclonal component with the
percentage of plasma cells (paraprotein index).
Univariate analysis of our patients pointed to the existence
of nine prognostic factors: poor performance status,
infections before diagnosis, renal insufficiency, hyper-
calcaemia, severe anaemia, Bence-Jones proteinuria, failure
to achieve complete remission, high plasma cell infiltration
and a low paraprotein index. Recently, Hansen & Galton
(1985) have reviewed the prognostic factors with significance
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for survival in myelomatosis; of them the only important one
that does not appear in our study is serum albumin
concentration (Alexanian et al., 1975; Bataille et al., 1979).
In our series, although hypoalbuminaemia (<3 gdl-1) was
associated with a shorter survival the differences were not
statistically significant. On the other hand, infections before
diagnosis, a feature which has not received much attention,
was associated with an adverse prognosis in our patients.
Recently, some new parameters, such as thymidine kinase
(Simonsson et al., 1985), T-cell subsets (San Miguel et al.,
1985), plasma cell morphology (Greipp et al., 1985), plasma
cell antigens (Ruiz Arguelles et al., 1984; San Miguel et al.,
1987), plasma cell labelling index (Durie et al., 1980) and
beta-2-microglobulin (Bataille et al., 1984; Brenning et al.,
1986; Cuzick et al., 1985; Van Dobbenburgh et al., 1985)
have emerged as possible prognostic factors in multiple
myeloma. Of all these, the latter has been the most
extensively analysed, being assessed in most studies as an
important prognostic variable (Bataille et al., 1984; Brenning
et al., 1986; Cuzick et al., 1985). Moreover, in a recent series
Cuzick et al. (1985) have shown that beta-2- microglobulin
was the most powerful independent prognostic factor. We
have studied this parameter in 58 MM patients and 21
patients with essential monoclonal gammopathy (data not
shown), and have found that the levels beta-2-microglobulin
correlated with both the amount of paraprotein and
advanced clinical stages and, in addition, could be a useful
parameter for the differential diagnosis of monoclonal
gammopathies (Ortega et al., 1986). These data show that
any analysis of prognostic factors in multiple myeloma
should in future include these new variables in order to
perfect the prognostic models that will permit a better
stratification of the patients and the evaluation of treatment
protocols.
In MM patients the M-component synthesized is
proportional to the total plasma cell mass (Salmon & Smith,
1970), but neither the monoclonal component nor the
percentage of plasma cells, in spite of being key criteria for
the diagnosis of MM, have a definite prognostic value
(Hansen & Galton, 1985). Accordingly, we thought it of
interest to search for a variable of easy clinical application
that would relate the production of Igs and plasma cells: the
paraprotein index (PI). In our series the patients with a low
PI had unfavourable clinico-biological features and shorter
survivals. The low capacity of Ig synthesis of these cases
could reflect the existence of a blockage in Ig secretion (Qian
et al., 1984), and it would be important to rule out that these
plasma cells might be at an earlier stage of maturation that
could be associated with a different response to
chemotherapy (San Miguel et al., 1987).
Although multivariate analyses are much scarcer (Blade &
Rozman, 1984; Cohen et al., 1979; Durie & Salmon, 1975;
Durie et al., 1980; Hernandez & San Miguel, 1984; Kyle,
1983, 1984; Matzner et al., 1978; Merlini et al., 1980), they
have the advantage of considering the simultaneous effect of
the different variables on survival, which facilitates the
grouping of patients according to the real major prognostic
features. The method most commonly employed is the
stepwise proportional hazards regression model of Cox (Cox,
1972; Cox & Dakes, 1985). Using this method in our series
the best combination of independent prognostic variables in
predicting survival was renal function and performance
status. These two factors, together with haemoglobin and to
a lesser extent calcium, have been those identified with the
highest frequency as a significant risk factor in other
multivariate analyses (Hansen & Galton, 1985; Harley et al.,
1979; Matzner et al., 1978; Merlini et al., 1980).
Using principal component analysis, a statistical approach
that has only been used occasionally, we found that the
combination of clinical performance status, serum creatinine,
haemoglobin and paraprotein index allowed us to
discriminate three groups of patients with different survivals.
This staging system provided very similar results to those of
the MRC (1980), with an even lower level of wrongly
classified patients. This is understandable since both models
contain similar criteria, with the exception of the paraprotein
index which hitherto has not been explored. In contrast, and
as evidenced by other studies (Bettini et al., 1983; Blade &
Rozman, 1984; Durie et al., 1980; Gavagnaro et al., 1980;
Gassmann et al., 1985; Hansen & Galton, 1985; Hernandez
& San Miguel, 1984; Merlini et al., 1980; Vercelli et al.,
1981), the staging systems proposed by Merlini et al. (1980),
Durie & Salmon (1975) and Carbone et al. (1967) did not
discriminate prognostic subgroups.
Our study thus indicates that principal component analysis
may be a useful complementary tool for classifying patients
according to prognostic factors and the paraprotein index
could be a simple parameter of great use in clinical practice.
This work was partially supported by a grant from the Educational
Council of Castilla-Leon (Spain) and the Spanish Cancer
Association.
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